Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · USD

$28.9

+3.95 (+15.9%)· Recorded snapshot

Market cap	2.9B
Revenue (ttm)	156M
Net income (ttm)	-86.5M
EPS (ttm)	-$0.84
Shares out	99.9M
Volume	4,396,320
Beta	2.20

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 156M
Net income (ttm): -86.5M
EPS (ttm): -$0.84
Market cap: 2.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-8.2

P25 n/aP50 n/aP75 n/a

ROIC-18.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BEAM indicators

Market & fundamental data

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001745999
Company name	Beam Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	07373V105
Earnings date	2026-11-10
Earnings time	bmo
Employees	540
Employees change	31
Employees growth	6.09%
Enterprise value	$2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-02-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US07373V1052
Last 10-K release date	2026-02-24
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.9B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$28.85
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	BEAM
U.S. state	Massachusetts
Website	https://beamtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-2.9%
EV/Sales	10.78x
FCF / EV yield	-22.16%
FCF yield	-14.4%
Forward EV/Sales	33.65x
Forward P/S	51.76x
P/B ratio	2.33x
P/S ratio	16.59x
Price / tangible book value	2.42x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-242.27%
EBITDA margin	-228.01%
Gross margin	-161.91%
Operating margin	-242.27%
Pretax margin	-55.45%
Profit margin	-55.45%
Profit per employee	$-160,222
Revenue per employee	$288,954
ROA	-17.01%
ROA (5Y)	-15.43%
ROCE	-28.96%
ROE	-8.18%
ROE (5Y)	-34.74%
ROIC	-18.78%
SBC / revenue	52.24%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	158.89%
Revenue growth (Q)	-94.21%
Revenue growth (QoQ)	-98.46%
Revenue growth 3Y	24.86%
Revenue growth 5Y	478.9%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-13.4M
Depreciation and amortization	$22.2M
EBIT	$-378M
EBITDA	$-355.8M
EPS	$-0.84
FCF per share	$-3.73
Financing cash flow	$107.7M
Free cash flow	$-372.8M
Free cash flow minus SBC	$-454.3M
Gross profit	$-252.6M
Investing cash flow	$189.5M
Net borrowing	$93.9M
Net cash flow	$-62.2M
Net income	$-86.5M
Operating cash flow minus SBC	$-440.9M
Operating income	$-378M
Revenue	$156M
Stock-based compensation	$81.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.08
Book value per share	$10.68
Debt / equity	0.23
Long-term assets	$207.8M
Long-term liabilities	$238M
Net cash (debt)	$905.6M
Net cash / market cap	34.99%
Net cash growth	-9.04%
Net debt / equity	-0.85
Piotroski F-Score	3
Property, plant and equipment	$193.2M
Shareholders' equity	$1.1B
Tangible book value	$1.1B
Tangible book value per share	$10.68
Total assets	$1.4B
Total cash	$1.2B
Total debt	$247.4M
Total liabilities	$318.9M
WACC	14.93%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.11
Current assets	$1.2B
Current liabilities	$80.9M
Current ratio	14.57
Net working capital	$-40M
Quick ratio	14.25
Working capital	$1.1B
Working capital turnover	0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-16.29%
Dividend yield	0%
Shareholder yield	-16.29%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$28.27
1D price change	15.86%
1M price change	17.18%
1M total return	17.18%
1W price change	14.08%
1W total return	14.08%
1Y price change	6.4%
1Y return CAGR	6.4%
1Y total return	6.4%
20-day SMA	$24.80
200-day SMA	$28.21
3M price change	13.44%
3M total return	13.44%
3Y price change	52.74%
3Y return CAGR	15.16%
3Y total return	52.74%
50-day SMA	$25.95
50-day SMA vs 200-day SMA	50under200
52-week high	$38.26
52-week high date	2026-07-07
52-week low	$20.23
52-week low date	2025-11-20
5Y price change	-69.02%
5Y return CAGR	-20.89%
5Y total return	-69.02%
6M price change	-2.49%
6M total return	-2.49%
All-time high	$138.52
All-time high date	2021-07-02
All-time low	$13.00
All-time low date	2020-03-16
Average true range (ATR)	$1.50
Average volume	1.9M
Beta (1Y)	2.83
Beta (2Y)	2.32
Beta (5Y)	2.2
Change from 52-week high	-24.59%
Change from 52-week low	42.61%
Change from all-time high	-79.47%
Change from all-time low	118.77%
Change from open	16.66%
Day's gap	-0.68%
Dollar volume	$126.8M
High price	$28.86
Low price	$24.56
Monthly RSI	51.11
Open price	$24.73
Position in 52-week range	99.77%
Premarket change	0.84%
Premarket close	$24.90
Premarket price	$25.11
Premarket volume	15K
Previous close	$24.90
Price vs 150-day SMA	0.59%
Price vs 20-day SMA	14.69%
Price vs 200-day SMA	0.83%
Price vs 50-day SMA	9.6%
Relative volume	2.36
Return from IPO open	7.92%
Return from IPO price	52.35%
RSI	65.44
Sharpe ratio	0.38
Sharpe ratio (3Y)	0.49
Sharpe ratio (5Y)	-0
Sortino ratio	0.7
Sortino ratio (3Y)	0.87
Sortino ratio (5Y)	0.08
Volume	4.4M
Weekly RSI	53.02
YTD price change	2.6%
YTD total return	2.6%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	88.3M
Float percentage	88.4%
Shares change (QoQ)	1.03%
Shares change (YoY)	16.29%
Shares held by insiders	1.36%
Shares held by institutions	96.56%
Shares outstanding	99.9M
Short % of float	29.71%
Short % of shares	26.26%
Short ratio	14.3 days

Deeper analysis on BEAM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BEAM report

Is a complete BEAM research report available?

No complete published report is available for Beam Therapeutics Inc. (BEAM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Beam Therapeutics Inc. (BEAM)

Price

Financial snapshot

Fair-value bridge

Latest news · BEAM

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BEAM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BEAM

Frequently asked questions